Results 161 to 170 of about 18,010 (199)

<i>In vitro</i> activity of meropenem-vaborbactam plus aztreonam against metallo-β-lactamase-producing <i>Klebsiella pneumoniae</i>. [PDF]

Antimicrob Agents Chemother
Cienfuegos-Gallet AV, Shashkina E, Chu T, Zhu Z, Wang B, Kreiswirth BN, Chen L.   +6 more
europepmc   +1 more source

In Vitro Susceptibility of Nonfermenting Gram-Negative Rods To Meropenem–Vaborbactam and Delafloxacin

Future Microbiology, 2023
Aim: Meropenem-vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. (Achr), Burkholderia cepacia complex (Bcc) and Stenotrophomonas maltophilia (Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with gradient diffusion test of meropenem-vaborbactam, delafloxacin and comparators.
Farfour, Eric, D’epenoux, Louise Ruffier, Muggeo, Anaëlle, de Verdière, Sylvie, Alauzet, Corentine, Crémet, Lise, Moussalih, Sophie, Roux, Antoine, Vasse, Marc, Bosphore, Amélie, Corvec, Stéphane, Guillard, Thomas   +11 more
core   +8 more sources

Some of the next articles are maybe not open access.

Related searches:

In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme

International Journal of Antimicrobial Agents, 2018
The activity of meropenem/vaborbactam was evaluated against 11 559 Enterobacteriaceae isolates, including 330 carbapenem-resistant phenotypes (CRE) and carbapenemase genotypes collected worldwide during 2015. Antimicrobial susceptibility testing for meropenem/vaborbactam (inhibitor at 8 mg/L) and comparators was performed by the reference broth ...
Rodrigo Mendes, Michael Huband, Mariana Castanheira   +2 more
exaly   +3 more sources

Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination

Annals of Pharmacotherapy, 2018
Objective: To review the pharmacology, spectrum of activity, pharmacokinetics, pharmacodynamics, safety, efficacy, administration, and considerations for clinical use of meropenem/vaborbactam (M/V). Data Sources: A literature search using PubMed and clinicaltrials.gov (June 2013 to December 2017) was conducted using the search terms meropenem ...
Jonathan C, Cho, Monika T, Zmarlicka, Kristy M, Shaeer, Joe, Pardo   +3 more
openaire   +3 more sources

Meropenem / Meropenem-vaborbactam

, 2017
Meropenem is a broad-spectrum parenteral carbapenem with antimicrobial activity against a wide range of Gramnegative and Gram-positive bacteria, including anaerobes. As a consequence of emerging multidrug resistance, especially in Gram-negative organisms, the clinical reliance on meropenem and other carbapenems increased after their introduction ...
Peleg, A. Y., Harris, P.
openaire   +4 more sources

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2018
Meropenem-vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae .
Olga Lomovskaya, Mojgan Sabet
exaly   +2 more sources

Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae

Antimicrobial Agents and Chemotherapy, 2017
We evaluated the activity of meropenem-vaborbactam against contemporary nonfastidious Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistance phenotypes and carbapenemase genotypes.
Rodrigo Mendes, Michael Huband, Mariana Castanheira   +2 more
exaly   +2 more sources

An Update on Existing and Emerging Data for Meropenem-Vaborbactam

Clinical Therapeutics, 2020
The search for new agents to treat multidrug-resistant gram-negative bacterial infections has been ongoing. Specifically, carbapenem-resistant Enterobacteriaceae (CRE) infections often exhibit multiple resistance mechanisms, including alterations in drug structure, bacterial efflux pumps, and drug permeability.
Bethany R, Shoulders, Anthony M, Casapao, Veena, Venugopalan   +2 more
openaire   +2 more sources